ESR1 and breast cancer: Thus, while the bulk of the tumor cell population (already moderately differentiated) is relatively resistant, the tumor stem cells underlying ER-positive breast cancer, which are actually ER-negative [56] and highly undifferentiated, appear to be highly sensitive to IRES inhibition (manuscript in preparation).